Revenue $16.99B, up 10.2% on a year earlier. Global Humira Net Revenues $756.00M, down 35.9%. Aesthetics Portfolio Net Revenues $1.28B, up 0.2%. Diluted EPS $2.03 against $0.52.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $16.99B | $15.00B | $15.42B | +10.2% |
| Operating income | $6.43B | $3.99B | $4.89B | +31.4% |
| Net income | $3.62B | $697.00M | $941.00M | +284.3% |
| Diluted EPS | $2.03 | $0.39 | $0.52 | |
| Operating cash flow | $3.44B | $3.83B | $5.15B | -33.3% |
| Capital expenditures | -$322.00M | -$265.00M | -$269.00M | |
| Free cash flow | $3.11B | $3.56B | $4.88B | -36.2% |
| Dividend per share | $1.73 | $1.73 | $1.64 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Global Humira Net Revenues | $756.00M | $1.18B | -35.9% |
| Aesthetics Portfolio Net Revenues | $1.28B | $1.28B | +0.2% |
| International Humira Net Revenues | $331.00M | $378.00M | -12.4% |
| U.S. Humira Net Revenues | $425.00M | $802.00M | -47.0% |
| Adjusted Net Revenues Growth | 9.5% | 6.6% | |
| Global Imbruvica Net Revenues | $532.00M | $754.00M | -29.4% |
| Oncology Portfolio Net Revenues | $1.65B | $1.68B | -1.6% |
| Immunology Portfolio Net Revenues | $8.79B | $7.63B | +15.1% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “AbbVie (ABBV) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/ABBV/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
